Author:
Chan Chilam,Lustig Marta,Baumann Niklas,Valerius Thomas,van Tetering Geert,Leusen Jeanette H. W.
Abstract
Immunotherapy with therapeutic antibodies has shown a lack of durable responses in some patients due to resistance mechanisms. Checkpoint molecules expressed by tumor cells have a deleterious impact on clinical responses to therapeutic antibodies. Myeloid checkpoints, which negatively regulate macrophage and neutrophil anti-tumor responses, are a novel type of checkpoint molecule. Myeloid checkpoint inhibition is currently being studied in combination with IgG-based immunotherapy. In contrast, the combination with IgA-based treatment has received minimal attention. IgA antibodies have been demonstrated to more effectively attract and activate neutrophils than their IgG counterparts. Therefore, myeloid checkpoint inhibition could be an interesting addition to IgA treatment and has the potential to significantly enhance IgA therapy.
Subject
Immunology,Immunology and Allergy
Reference207 articles.
1. FDA Approves 100th Monoclonal Antibody Product;Mullard;Nat Rev Drug Discovery,2021
2. Immunoreceptor Tyrosine-Based Inhibition Motifs: A Quest in the Past and Future;Daëron;Immunol Rev,2008
3. The Future of Immune Checkpoint Therapy;Sharma;Science,2015
4. The Checkpoint Immunotherapy Revolution: What Started as a Trickle Has Become a Flood, Despite Some Daunting Adverse Effects; New Drugs, Indications, and Combinations Continue to Emerge;Alexander;P T,2016
5. Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics;Twomey;AAPS J,2021
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献